ExeVir develops novel antibody therapies capable of preventing and treating current public health threats and responding to future outbreaks with speed and agility
ExeVir develops novel antibody therapies capable of preventing and treating current public health threats and responding to future outbreaks with speed and agility. Their unique modular VHH platform utilizes camelid antibody fragments to create new therapeutic compounds that are stable, cost-effective, and easy to produce.